Aptevo Operating Cycle from 2010 to 2026

APVO Stock  USD 7.27  0.12  1.62%   
Aptevo Therapeutics Operating Cycle yearly trend continues to be very stable with very little volatility. Operating Cycle is likely to grow to 368.76 this year. During the period from 2010 to 2026, Aptevo Therapeutics Operating Cycle quarterly data regression pattern had sample variance of  51,804 and median of  336.99. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
336.99
Current Value
368.76
Quarterly Volatility
227.60456007
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Aptevo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aptevo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 301 K, Interest Expense of 43.1 M or Selling General Administrative of 18.3 M, as well as many indicators such as Price To Sales Ratio of 4.15, Dividend Yield of 0.0 or PTB Ratio of 0.27. Aptevo financial statements analysis is a perfect complement when working with Aptevo Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Aptevo Stock
Check out the analysis of Aptevo Therapeutics Correlation against competitors.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.
Evaluating Aptevo Therapeutics's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Aptevo Therapeutics's fundamental strength.

Latest Aptevo Therapeutics' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Aptevo Therapeutics over the last few years. It is Aptevo Therapeutics' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aptevo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Slightly volatile
   Operating Cycle   
       Timeline  

Aptevo Operating Cycle Regression Statistics

Arithmetic Mean375.07
Geometric Mean311.59
Coefficient Of Variation60.68
Mean Deviation174.62
Median336.99
Standard Deviation227.60
Sample Variance51,804
Range899
R-Value(0.32)
Mean Square Error49,426
R-Squared0.11
Significance0.20
Slope(14.64)
Total Sum of Squares828,861

Aptevo Operating Cycle History

2026 368.76
2025 336.99
2022 293.03
2021 108.8
2020 200.67
2019 1002.57
2018 140.7

About Aptevo Therapeutics Financial Statements

Aptevo Therapeutics investors utilize fundamental indicators, such as Operating Cycle, to predict how Aptevo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cycle 336.99  368.76 

Pair Trading with Aptevo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Aptevo Stock

  0.63EVGN EvogenePairCorr
  0.66IMNN Imunon IncPairCorr
  0.63IPHA Innate PharmaPairCorr
  0.78LYRA Lyra TherapeuticsPairCorr
  0.8MBIO Mustang BioPairCorr

Moving against Aptevo Stock

  0.88MRKR Marker TherapeuticsPairCorr
  0.84CING CingulatePairCorr
  0.79AEON AEON BiopharmaPairCorr
  0.71ARWR Arrowhead PharmaceuticalsPairCorr
  0.65BOLT Bolt BiotherapeuticsPairCorr
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Aptevo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptevo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptevo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptevo Therapeutics Stock:
Check out the analysis of Aptevo Therapeutics Correlation against competitors.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Will Biotechnology sector continue expanding? Could Aptevo diversify its offerings? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aptevo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
7.8 K
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.79)
Return On Equity
(2.43)
Understanding Aptevo Therapeutics requires distinguishing between market price and book value, where the latter reflects Aptevo's accounting equity. The concept of intrinsic value—what Aptevo Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aptevo Therapeutics' price substantially above or below its fundamental value.
Understanding that Aptevo Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aptevo Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aptevo Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.